A method to monitor mRNA levels in human breast tumor cells obtained by fine-needle aspiration

Diagnostic Molecular Pathology

Volumn 6, Issue 6, 1997, Pages 353-360

  De Lange, Majella S ^a   Top, Bert ^a,b   Lambrechts, Caro ^a   Maas, Riks A ^a,c   Peterse, Hans L ^a   Mooi, Wolter J ^a,d   Van't Veer, Laura J ^a   Rodenhuis, Sjoerd ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Organon Teknika   (Netherlands)

^c WAGENINGEN UNIVERSITY   (Netherlands)

^d ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PORPHOBILINOGEN DEAMINASE;

ARTICLE; ASPIRATION BIOPSY; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; NORTHERN BLOTTING; ONCOGENE C ERB; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS;

BIOPSY, NEEDLE; BLOTTING, NORTHERN; BRCA1 PROTEIN; BREAST NEOPLASMS; FEASIBILITY STUDIES; FEMALE; GENE EXPRESSION; HUMANS; POLYMERASE CHAIN REACTION; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0031430217     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019606-199712000-00008     Document Type: Article

References (21)

1. Alt FW, Kellems RE, Bertino JR, Schimke RT. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J Biol Chem 1978;253: 1357-70.
2. Burt RK, Poirier MC, Link JR CJ, Bohr VA. Antineoplastic drug resistance and DNA repair. Ann Oncol 1993;2:325-34.
3. Coussens L, Yang-Feng TL, Chen YCLE, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-9.
4. Daffada AAI, Johnston SRD, Smith IE, Detre S, King N, Dowsett M. Exon 5 deletion variant estrogen receptor messenger RNA expression relation to tamoxifen resistance and progesterone receptor /pS2 status in human breast cancer. Cancer Res 1995;55:288-93.
5. Dorr FA. Prognostic factors observed in current clinical trials. Cancer 1993;71(suppl):2168-73.
6. Finke J, Fritzen R, Ternes P, Lange W, Dolken G. An improved strategy and a useful housekeeping gene for RNA analysis from formalin-fixed, paraffin-embedded tissues by PCR. Biotechniques 1993;14:448-53.
7. Gause WC, Adamovicz J. Use of PCR to quantitate relative differences in gene expression. In: Dieffenbach CW, Dveksler GS, eds. PCR primer. A laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1995.
8. Grandchamp B, De Verneuil H, Beaumont C, Chretien S, Walter O, Nordmann Y. Tissue-specific expression of porphobilinogen deaminase: two isoenzymes from a single gene. Eur J Biochem 1987;162:105-10.
9. Hille Van B, Lohn A, Reuter J, Herrman R. Assessment of drug-induced dysregulations among seven resistance-associated genes in human tumour cell lines. Anticancer Res 1996;16:3531-6.
10. Lin JH, Grandchamp B, Abraham NG. Quantitation of human erythroid-specific porphobilinogen deaminase mRNA by the polymerase chain reaction. Exp Hematol 1991;19:817-22.
11. Maas RA, Bruning PF, Breedijk AJ, Top B, Peterse HL. Immunomagnetic purification of human breast carcinoma cells allows tumor-specific detection of multidrug resistance gene 1-mRNA by reverse transcriptase polymerase chain reaction in fine-needle aspirates. Lab Invest 1995;72:760-4.
12. Maas RA, Bruning PF, Top B, Breedijk AJ, Peterse HL. Growth arrest associated changes of mRNA levels in breast cancer cells measured by semi-quantitative RT-PCR: potential early indicators of treatment response. Cancer Lett 1995;97:107-16.
13. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
14. Murphy LD, Herzog CE, Rudick JB, Fojo AT, Bates SE. Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. Biochemistry 1990;13:10351-6.
15. Osborn CK, Fuqua SAW. Mechanisms of tamoxifen resistance. Breast Cancer Res Treat 1994;32:49-55.
16. Preisler HD. Multidrug resistance is more than MDR1 activity. Leukemia Res 1995;19:429-31.
17. Roca J. The mechanisms of DNA topoisomerases. Trends Biochem Sci 1995;20:156-60.
18. Sikic BI. Modulation of multidrug resistance: at the threshold. J Clin Oncol 1993;11:1629-35.
19. Tonetti DA, Jordan VC. Possible mechanisms in the emergence of tamoxifen-resistant breast cancer. Anticancer Drugs 1995;6:498-507.
20. Wang FS, Aschele C, Sobrero A, Chang YM, Bertino JR. Decreased folylpolyglutamate synthetase expression: a novel mechanism of fluorouracil resistance. Cancer Res 1993;53:3677-80.
21. Zhao S, Consoli U, Arceci R, Pfeifer J, Dalton WS, Andreeff M. Semi-automated PCR method for quantitating MDR1 expression. Biotechniques 1996;21:726-31.